Kannalife, Inc. Receives Patent Grants in Additional European Territories
August 25, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development...
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
June 30, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development...
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors
June 02, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of...
Kannalife, Inc. CEO Op-Ed Featured in Green Entrepreneur Magazine’s Latest Edition
April 28, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., April 28, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of...
Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain
April 16, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., April 16, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of...
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD
April 14, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of...
UPDATE – Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
April 01, 2020 11:23 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of...
Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders
March 18, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical med-chem company specializing in the research and development of...
Kannalife, Inc. Receives Patent in the European Union (EU) for its Novel Monotherapeutic Compound to Treat CNS and PNS Disorders
March 03, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical med-chem company specializing in the research and development of...
Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent
February 18, 2020 09:00 ET
|
Kannalife, Inc.
DOYLESTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...